Ligand Pharmaceuticals Incorporated (LGNDZ)

Market Cap	3.66B +65.2%
Revenue (ttm)	251.23M +64.8%
Net Income	48.58M +7.4%
EPS	2.49 +0.8%
Shares Out	n/a
PE Ratio	75.34
Forward PE	22.55
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,000
Average Volume	51,373
Open	0.0053
Previous Close	n/a
Day's Range	0.0053 - 0.0060
52-Week Range	0.0006 - 0.0129
Beta	1.04
RSI	48.41
Earnings Date	Feb 11, 2026

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neurobla...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1987
• Employees: 68
• Stock Exchange: OTCMKTS
• Ticker Symbol: LGNDZ